Søholm, Uffe
Broadley, Melanie
Zaremba, Natalie
Divilly, Patrick
Baumann, Petra Martina
Mahmoudi, Zeinab
Martine-Edith, Gilberte
Mader, Julia K.
Cigler, Monika
Brøsen, Julie Maria Bøggild
Vaag, Allan
Heller, Simon
Pedersen-Bjergaard, Ulrik
McCrimmon, Rory J.
Renard, Eric
Evans, Mark
de Galan, Bastiaan
Abbink, Evertine
Amiel, Stephanie A.
Hendrieckx, Christel
Speight, Jane
Choudhary, Pratik
Pouwer, Frans
,
Funding for this research was provided by:
Innovative Medicines Initiative 2 Joint Undertaking (No 777460)
University of Southern Denmark
Article History
Received: 22 February 2024
Accepted: 29 April 2024
First Online: 30 July 2024
Acknowledgements
: The authors thank the people with diabetes who participated in the Hypo-METRICS study for their support. The authors also thank Abbott Diabetes Care for providing the CGM devices used in the study and uMotif Limited for providing the platform for the Hypo-METRICS app.
: The data underlying the results presented in the study are available from the Hypo-RESOLVE data repository for researchers who meet the criteria for access. Please contact Hypo-RESOLVE for further details (chair of the publication committee Professor Stephanie Amiel or principal investigator Professor Pratik Choudhary; ).
: Open access funding provided by University of Southern Denmark. This work was supported by the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement no 777460. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and type 1 diabetes Exchange, JDRF, IDF and The Leona M. and Harry B. Helmsley Charitable Trust. The industry partners supporting the JU include Abbott Diabetes Care, Eli Lilly, Medtronic, Novo Nordisk and Sanofi-Aventis. The funder had no role in the design of the project or its work packages, the collection or analysis of data, the writing of the manuscript or the decision to submit for publication. This paper reflects the authors views and the JU is not responsible for any use that may be made of the information it contains. JS and CH are supported by core funding to the Australian Centre for Behavioural Research in Diabetes provided by the collaboration between Diabetes Victoria and Deakin University. GME’s position at King’s College London is funded by a grant from Novo Nordisk. The University of Cambridge has received salary support for MLE through the National Health Service in the East of England, through the Clinical Academic Reserve and work supported by the NIHR Cambridge Biomedical Research Centre and carried out in the NIHR Cambridge Clinical Research Facility/Translational Research Facility. This study represents independent research supported by the National Institute for Health and Care Research (NIHR) King’s Clinical Research Facility and the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health and Social Care.
: US worked for Novo Nordisk A/S during the development of this manuscript. SAA has served on advisory boards for Novo Nordisk and Medtronic and has spoken at educational events sponsored by Novo Nordisk and Sanofi. SH has received research funding from Dexcom Inc. and served on advisory boards for Eli Lilly, Zealand Pharma and Zucara. He has spoken at educational events sponsored by NovoNordisk and is currently an Independent Chair of a Data Monitoring and Safety Committee on behalf of Eli Lilly. FP has received unrestricted funding for research from Novo Nordisk, Eli Lilly and Sanofi. JS has served on advisory boards for Insulet, Janssen, Medtronic, Roche Diabetes Care and Sanofi Diabetes, has received unrestricted educational grants and in-kind support from Abbott Diabetes Care, AstraZeneca, Medtronic, Roche Diabetes Care and Sanofi Diabetes, has received sponsorship to attend educational meetings from Medtronic, Roche Diabetes Care and Sanofi Diabetes, and has received consultancy income or speaker fees from Abbott Diabetes Care, AstraZeneca, Medtronic, Novo Nordisk, Roche Diabetes Care and Sanofi Diabetes. In all cases, her research group (the Australian Centre for Behavioural Research in Diabetes [ACBRD]) has been the beneficiary of these funds. JKM is a member in the advisory board of Abbott Diabetes Care, Becton-Dickinson/embecta, Biomea Fusion, Boehringer Ingelheim, Eli Lilly, Medtronic, Novo Nordisk, Roche Diabetes Care, Pharmasens, Prediktor SA, Sanofi and Viatris and has received speaker honoraria from Abbott Diabetes Care, AstraZeneca, Becton-Dickinson/embecta, Eli Lilly, Dexcom, Medtronic, Medtrust, Menarini, Novo Nordisk, Roche Diabetes Care, Sanofi, Servier, Viatris and Ypsomed. She is a shareholder of decide Clinical Software GmbH and elyte Diagnostics GmbH. ER reports serving on advisory boards for Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom Inc, Insulet, Sanofi, Roche Diabetes Care, Novo Nordisk and Eli Lilly, and has received research support from Dexcom Inc and Tandem. ME has served on advisory boards/received speakers fees from NovoNordisk, Eli Lilly, Abbott Diabetes Care, Medtronic, Dexcom, Pila Pharma and Zucara. RJM has served on advisory boards/received speakers fees from Sanofi and Novo Nordisk. UP-B has served on advisory boards for Sanofi-Aventis, Novo Nordisk and Vertex and has received lecture fees from Abbott, Sanofi-Aventis and Novo Nordisk. BdG and SH have received research funding from Novo Nordisk. UP-B and BdG are members of the editorial board of Diabetologia. The other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
: All authors made substantial contributions to the conception and design of the Hypo-METRICS study. US, MB, CH, JS, PC and FP developed the plan for this specific manuscript, with input and advice from the remaining co-authors. PMB, ZM and GM-E advised on the analysis plan, and US conducted all analyses. US prepared the first manuscript draft, with critical feedback from MB, JS, CH, PC and FP. US prepared subsequent revisions with feedback from all authors. All authors approved the final draft of the manuscript. US is the guarantor of this work.